Argentum Medical, LLC

Argentum Medical, LLC, doing business as Bravida Medical, manufactures and distributes advanced antimicrobial wound dressings and specialized medical supplies to the Department of Defense and Department of Veterans Affairs as a prime contractor, with 97% of recent awards in that role. The company is a for-profit limited liability company headquartered in Geneva, Illinois, competing full-and-open across all prime awards with no set-aside designations. Argentum Medical competes predominantly under two parent indefinite delivery vehicles: a $14.78 million single-award contract with Defense Logistics Agency Troop Support Medical through August 2025 (designated total small business set-aside on the master vehicle, though individual delivery orders carry no set-aside), and a $1.5 million Federal Supply Schedule contract with the Department of Veterans Affairs through January 2029 under the Medical Equipment and Supplies schedule.

The vendor's portfolio is heavily concentrated in a single customer and vehicle. The Defense Logistics Agency Troop Support Medical accounts for 588 of 599 awards (98% by count) and generates $15.7 million in combined potential value through the SPE2DE20D0018 indefinite delivery contract, which has issued 523 task orders. However, the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response drives the majority of dollar value: four awards totaling $87 million potential value, anchored by a $19.077 billion delivery order on the GSA Federal Supply Schedule for Silverlon burn contact dressing (4 inches by 66 inches) awarded September 8, 2025, with performance through September 2030. Additional ASPR work includes smaller delivery orders for antimicrobial burn dressing and similar products. This represents a material recompete cliff: the DLA indefinite delivery contract expires August 2025, and the $14.78 million vehicle ceiling faces potential non-renewal.

Argentum Medical's core capability centers on its proprietary Silverlon line of silver-plated nylon fabric wound dressings designed to prevent infection and promote healing, available in multiple sizes and configurations (66 inches by 4 inches, 108 inches by 6 inches, 4 inches by 4 inches, 14 inches by 4 inches, and 8 inches by 12 inches nanocrystalline variant) with seven-day antimicrobial benefit. Representative DLA delivery orders include $7.012 billion for 108-by-6-inch Silverlon dressing (July 5, 2025), $6.747 billion for 66-by-4-inch variant (July 24, 2025), and $4.948 billion for same (July 9, 2025). ASPR's $19.077 billion GSA FSS delivery order exercises an option ordering period for bulk Silverlon burn contact dressing procurement. Additional products include nanocrystalline silver dressings, burn contact dressings, and related wound care supplies. All recent prime awards carry firm fixed-price terms with no set-aside applied at the delivery-order level.

Activity has grown year over year through 2024 — 57 awards in 2022 to 193 in 2024 — then declined to 112 in 2025, reflecting wind-down of the expiring DLA indefinite delivery contract. The vendor operates primarily as a prime (584 of 599 awards), with minimal subcontractor footprint: Argentum Medical subcontracts to Cardinal Health 200, LLC on six medical and surgical equipment task orders since November 2023, supplying items such as reinforced staple lines, intraosseous infusion kits, hypothermia kits, and IV injection starter kits. The vendor has been registered in SAM since 2008 and holds no other named federal contract vehicles or positions on government-wide acquisition contracts. Dollar concentration is extreme: the $87 million ASPR award represents 83% of combined potential value, creating significant revenue visibility through 2030 but also concentration risk tied to a single customer and vehicle.